BioXcel Therapeutics BTAI Income Statement (2017-2026)

NASDAQ BTAI
$0.04 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT
Reported Financials

BioXcel Therapeutics Quarterly Income Statement

Periods 38 quarters
Latest Jun 2026

BioXcel Therapeutics reported revenue of $0.18M and net income of -$14.71M for the quarter ended Jun 2026, up 51.7% year over year. This income statement covers 38 quarters of results from Mar 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
1.75M1.75M1.75M1.75M1.75M1.76M1.82M1.83M1.83M1.87M2.10M2.52M2.65M2.54M5.47M6.62M14.20M12.21M27.07M31.30M
Revenue & cost
Revenue
0.14M0.24M0.21M0.46M0.34M0.38M0.58M1.10M0.21M0.37M0.17M0.12M0.10M0.26M0.21M0.18M
Gross Profit
0.13M0.23M0.20M0.43M-0.17M-0.34M0.50M1.04M-0.96M-0.47M0.15M0.01M0.09M0.22M-0.08M0.16M
Operating items
Research & DevelopmentR&D
11.93M12.53M18.56M17.91M22.06M32.46M27.80M26.97M19.62M9.93M11.40M8.03M5.10M5.90M4.55M10.26M8.74M6.70M2.96M3.16M
Selling, General & AdministrativeSG&A
14.88M13.61M12.92M18.38M17.05M20.66M23.59M25.87M24.34M9.60M13.26M9.45M7.68M4.09M5.70M5.61M5.38M3.81M7.19M7.19M
Restructuring CostsRestructuring
4.16M0.86M1.55M0.03M0.19M
Other Operating ExpensesOther Opex
0.01M0.01M0.01M0.03M0.51M0.71M0.08M0.06M1.17M0.83M0.01M0.11M0.01M0.03M0.28M0.02M
Operating ExpensesOpex
26.81M26.13M31.48M36.29M39.13M53.13M51.40M52.87M48.64M20.25M24.75M18.40M15.51M10.86M10.27M15.97M14.33M10.54M10.43M10.38M
Operating IncomeOp. Inc
-26.81M-26.13M-31.48M-36.29M-38.99M-52.89M-51.20M-52.41M-48.30M-19.88M-24.16M-17.30M-15.29M-10.49M-10.10M-15.85M-14.23M-10.28M-10.22M-10.19M
EBIT
-26.81M-26.13M-31.48M-36.29M-38.99M-52.89M-51.20M-52.41M-48.30M-19.88M-24.16M-17.30M-15.29M-10.49M-10.10M-15.85M-14.23M-10.28M-10.22M-10.19M
Non-operating items
Non Operating Interest Expenses
0.01M0.01M0.01M1.59M3.70M2.92M3.37M3.26M3.25M3.44M3.61M3.70M3.79M4.03M3.99M4.22M4.37M4.40M4.20M4.26M
Interest & Investment IncomeInt & Inv Inc
0.00M0.05M0.01M0.20M0.82M1.49M2.02M1.62M1.07M0.95M0.95M0.67M0.62M0.37M0.28M0.23M0.24M0.32M0.21M0.13M
Other Non Operating IncomeOther Non Op Inc.
0.06M-0.48M-0.25M0.54M-0.01M0.11M0.03M12.03M4.82M3.30M6.56M0.66M-12.55M1.81M1.52M-0.39M
Non Operating IncomeNon Op. Inc.
0.06M
Net income details
EBT
-26.82M-26.09M-31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M-14.36M-14.21M-14.32M
Profit After TaxPAT
-26.81M-26.12M-31.47M-37.67M-41.80M-54.81M-52.80M-53.52M-50.49M-22.26M-26.79M-8.30M-13.65M-10.86M-7.25M-19.19M-30.91M-12.54M-12.69M-14.71M
Income from Continuing OperationsIncome (Continuing)
-26.82M-26.09M-31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M-14.36M-14.21M-14.32M
Consolidated Net IncomeConsol Net Inc.
-26.82M-26.09M-31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M-14.36M-14.21M-14.32M
Income towards Parent CompanyParent Net Inc
-26.82M-26.09M-31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M-14.36M-14.21M-14.32M
Net Income towards Common StockholdersNet Income
-26.82M-26.09M-31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M-14.36M-14.21M-14.32M
Additional items
EPS (Basic)
-15.34-15.83-18.00-21.53-23.91-31.03-29.38-29.63-27.60-12.28-13.90-8.08-6.97-5.58-2.86-2.53-1.29-1.18-0.60-0.47
EPS (Diluted)
-15.34-15.83-18.00-21.53-23.91-31.03-29.38-29.63-27.60-12.28-13.90-8.08-6.97-5.58-2.86-2.53-1.29-1.18-0.60-0.47
Shares Outstanding
1.75M1.65M1.75M1.75M1.75M1.75M1.79M1.82M1.83M1.82M1.93M2.52M2.65M2.54M4.83M7.84M14.20M12.21M23.57M30.30M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
1.75M1.65M1.75M1.75M1.75M1.75M1.79M1.82M1.83M1.82M1.93M2.52M2.65M2.54M4.83M7.84M14.20M12.21M23.57M30.30M
EBITDA
-26.81M-26.13M-31.48M-36.29M-38.99M-52.89M-51.20M-52.41M-48.30M-19.88M-24.16M-17.30M-15.29M-10.49M-10.10M-15.85M-14.23M-10.28M-10.22M-10.19M
Interest ExpensesInt Expense
0.01M0.01M0.01M1.59M3.70M2.92M3.37M3.26M3.25M3.44M3.61M3.70M3.79M4.03M3.99M4.22M4.37M4.40M4.20M4.26M